Dr Miles Dalby trained in medicine at St Mary’s Hospital Paddington qualifying in 1990. He undertook his specialist cardiac training in London at St Mary’s Hospital and Harefield Hospital, going on to MD research Fellowship in Interventional Cardiology and platelet function at The Royal Brompton Hospital and subsequently an International Clinical Fellowship at the Pitie Salpetriere Hospital Paris. Dr Dalby was appointed to the staff of the Royal Brompton & Harefield NHS Foundation Trust in 2005. He works in the large Harefield Hospital Primary Angioplasty Heart Attack program having developed the clinical service to serve a catchment of approximately 2 Million with more than 1200 activations of the service annually. In addition Dr Dalby has lead the Pan London roll-out of the direct access program for High Risk Non STEMI patients direct from ambulance to the London Heart Attack Centres. Dr Dalby also leads the Transcatheter Aortic Valve Replacement (TAVI) program at Harefield Hospital.
Dr Dalby is an Honorary Senior Lecturer at Imperial College and has raised over £1 Million as lead and joint applicant in research studies in the management of Acute Coronary Syndromes and is actively engaged in future trial planning and fundraising. His research interests mirror his clinical specialties, leading a number of trials in the field of Interventional Cardiology. He currently is Co-Leading a large study of gait speed in heart attack patients with Dr Will Man in a collaborative venture between the Cardiovascular and Respiratory BRUs at the Trust. He is also the Principal Investigator for the DANCE study of immediate angioplasty for high risk Non ST Elevation Acute Coronary Syndromes and the APACS study of antiplatelet drug efficacy in Acute coronary Syndromes.
et al., 2023, Expedited transfer to a cardiac arrest centre for non-ST-elevation out-of-hospital cardiac arrest (ARREST): a UK prospective, multicentre, parallel, randomised clinical trial., Lancet, Vol:402, Pages:1329-1337
et al., 2023, Time to TAVI: streamlining the pathway to treatment, Open Heart, Vol:10, ISSN:2053-3624
et al., 2023, Midterm Outcomes in Patients With Aortic Stenosis Treated With Contemporary Balloon-Expandable and Self-Expanding Valves: Does Valve Size Have an Impact on Outcome?, Journal of the American Heart Association, Vol:12
et al., 2022, Improved Mid-term Survival in Aortic Stenosis Patients Treated With Small Self-Expanding vs Balloon- Expandable Transcatheter Heart Valves, 34th Annual Symposium on Transcatheter Cardiovascular Therapeutics (TCT), ELSEVIER SCIENCE INC, Pages:B186-B186, ISSN:0735-1097
et al., 2022, Outcomes of Patients Undergoing ViV TAVR With the Current-Generation Transcatheter Aortic Valves for Purely Regurgitant Surgical Bioprostheses, 34th Annual Symposium on Transcatheter Cardiovascular Therapeutics (TCT), ELSEVIER SCIENCE INC, Pages:B213-B213, ISSN:0735-1097